U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma

NORTH CHICAGO, Ill., Jan. 19, 2017 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) for the treatment of patient... Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, marginal zone lymphoma, Non-Hodgkin's Lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news